Abstract
Objective This research aimed to systematically review and summarize the influence of Renin-Angiotensin-Aldosterone System (RAAS) inhibitors on the outcome of COVID_19 patients with hypertension.
Methods Electronic databases; PubMed/Medline, CINAHL, the Cochrane Central Register of Controlled Trials, clinical trial.gov, and Google Scholar were searched from 2019 to June 1, 2020. Additionally, the references of identified articles were also searched.
Results A total of 9 articles comprising 3,823 patients were incorporated; 1416 patients on RAAS inhibitors and 3469 on non-RAAS inhibitors. The study demonstrated that the taking of RAAS inhibitors in COVID_19 patients with hypertension significantly reduced mortality where patients on RAAS inhibitors had a 27% decrease of mortality (RR = 0.73 [95% CI: 0.63- 0.85, p< 0.0001, I2 = 0%, random-effects model]) compared to those not taking ACEI/ARB. No significant association were observed in disease severity (RR = 0.92 (95% CI: 0.74- 1.14) and hospitalization (WMD = –2.33[95% CI: –5.60, 0.75]), random-effects model.
Conclusion This study supports RAAS inhibitors’ safe use among COVID_19 patients with hypertension.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was registered in the International Prospective Register of Systematic review with registration number CDR42020186477.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email address: TBB tamiratbekele12{at}gmail.com, TS tamepfsa{at}gmail.com; SD dserawit{at}std.must.ac.ug
Data Availability
N/A
List of abbreviations
- COVID_19
- Corona viral diseases 2019
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- CDC
- Center of Disease Control
- RAAS
- renin-angiotensin-aldosterone system
- ACEI
- Angiotensin-converting enzyme inhibitors
- ARB
- Angiotensin receptor blocker
- ACE2
- angiotensin-converting enzyme 2
- Ang II
- Angiotensin II
- PRISMA-P
- Systematic Review and Meta-Analysis Protocol
- RCTs
- randomized controlled trials
- CCB
- Calcium channel blocker.
